ImageneBio (NASDAQ:IMA) Announces Earnings Results, Beats Estimates By $0.27 EPS

ImageneBio (NASDAQ:IMA) issued its earnings results on Wednesday. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27, FiscalAI reports.

ImageneBio Trading Up 0.7%

Shares of ImageneBio stock traded up $0.04 during trading on Wednesday, hitting $5.75. The stock had a trading volume of 4,856 shares, compared to its average volume of 162,120. The firm has a market cap of $61.24 million, a price-to-earnings ratio of -0.99 and a beta of 0.76. ImageneBio has a 12 month low of $3.94 and a 12 month high of $16.47. The business’s 50-day moving average is $5.77 and its 200 day moving average is $5.97.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IMA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a report on Monday, June 29th. Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. Finally, Wall Street Zen cut ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Hedge Funds Weigh In On ImageneBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deep Track Capital LP bought a new position in ImageneBio in the 3rd quarter worth about $7,160,000. Blue Owl Capital Holdings LP grew its holdings in shares of ImageneBio by 52.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 823,785 shares of the company’s stock worth $5,684,000 after purchasing an additional 282,861 shares in the last quarter. Vanguard Group Inc. purchased a new position in shares of ImageneBio during the third quarter worth about $1,902,000. BML Capital Management LLC increased its position in shares of ImageneBio by 13.4% in the first quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock worth $1,004,000 after purchasing an additional 23,704 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of ImageneBio in the third quarter worth approximately $996,000. 75.00% of the stock is currently owned by hedge funds and other institutional investors.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.